Summary. Introduction and objective. The value ofacetylsalicilic acid (AAS) in the secondary prevention of ischémie stroke is well established. However, the optimum dose of AAS for stroke-threatrened patients remains unsettled. This paper reviews the pattern of adverse reactions to AAS and their relationship to the dosage of AAS evaluated. Method. All the clinical trials in which AAS was used as the sole antiaggregant in the secondary prevention of ischémie stroke were reviewed. The crude odds ratiofor the differentadverse reactions was calculatedusing three sub tests: AASversus placebo; AAS <330mg/dversus AAS >330 mg/d; and each dosage level versus a placebo. Results. There is an increased risk associated with the use of AAS as compared to a placebo with respect to gastrointestinal bleeding (OR 2.3,1C 95% (1.6-4.1)), peptic ulcer (10.1 2.5-85.2)), intracerebral hemorrhage (2.2 (1.3-4)) and other hemorrhagicphenomena (2.6 (2-3.3)). Conclusions. There seems to be a direct relationship between the dosage of AAS and the frequency with which adverse reactions occur, except in the case of intracerebral hemorrhage. In the latter case there was no relationship with the dose given (0.8 (0.5-1.4)). © 1997, REV1STA DE NEUROLOG1A.
|Journal||Revista de Neurologia|
|Publication status||Published - 1 Dec 1997|
- Dose of aspirin
- Intracerebral hemorrhage
- Ischémie stroke
- Platelet antiaggregation
- Stroke prevention